公开(公告)号：CA2797138C

公开(公告)日：2018-10-02

申请号：CA2797138

申请日：2011-04-22

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： RISER BRUCE L ,  WHITE JEFFREY A ,  DALTON CHRISTOPHER R

IPC: A61K33/42 ,  A61K9/08 ,  A61P9/10

Abstract: Methods and compositions for reducing, preventing or reducing the progression of calcification in peritoneal dialysis patients are provided. In an embodiment, the present disclosure provides a method comprising administering to a patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 µM and about 400 µM. Formulations of dialysis solutions according to the dose ranges claimed in the present disclosure allow therapeutic amounts of pyrophosphate to be delivered to peritoneal dialysis patients.

公开(公告)号：ES2592938T3

公开(公告)日：2016-12-02

申请号：ES11717157

申请日：2011-04-22

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： RISER BRUCE L ,  WHITE JEFFREY A ,  DALTON CHRISTOPHER R

IPC: A61K33/42 ,  A61K9/08 ,  A61P9/10

Abstract: Una solución de diálisis que comprende una cantidad terapéuticamente efectiva de pirofosfato que varía entre aproximadamente 30 μM y aproximadamente 400 μM para su uso en reducir o evitar la progresión de la calcificación vascular en un paciente mediante la administración durante terapia de diálisis peritoneal.

公开(公告)号：AU2015200995B2

公开(公告)日：2016-09-08

申请号：AU2015200995

申请日：2015-02-26

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： RISER BRUCE L ,  WHITE JEFFREY A ,  DALTON CHRISTOPHER R

IPC: A61K33/42 ,  A61K9/08 ,  A61P9/10

Abstract: Abstract A method of reducing, preventing or reducing the progression of vascular calcification in a patient, the method comprising administering to the patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 pM and about 400 pM.

公开(公告)号：AU2015200995A1

公开(公告)日：2015-03-19

申请号：AU2015200995

申请日：2015-02-26

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： RISER BRUCE L ,  WHITE JEFFREY A ,  DALTON CHRISTOPHER R

IPC: A61K33/42 ,  A61K9/08 ,  A61P9/10

Abstract: Abstract A method of reducing, preventing or reducing the progression of vascular calcification in a patient, the method comprising administering to the patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 pM and about 400 pM.

公开(公告)号：SG184933A1

公开(公告)日：2012-11-29

申请号：SG2012077533

申请日：2011-04-22

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： RISER BRUCE L ,  WHITE JEFFREY A ,  DALTON CHRISTOPHER R

Abstract: Methods and compositions for reducing, preventing or reducing the progression of calcification in peritoneal dialysis patients are provided. In an embodiment, the present disclosure provides a method comprising administering to a patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 µM and about 400 µM. Formulations of dialysis solutions according to the dose ranges claimed in the present disclosure allow therapeutic amounts of pyrophosphate to be delivered to peritoneal dialysis patients.

公开(公告)号：CA2797138A1

公开(公告)日：2011-10-27

申请号：CA2797138

申请日：2011-04-22

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： RISER BRUCE L ,  WHITE JEFFREY A ,  DALTON CHRISTOPHER R

IPC: A61K33/42 ,  A61K9/08 ,  A61P9/10

Abstract: Methods and compositions for reducing, preventing or reducing the progression of calcification in peritoneal dialysis patients are provided. In an embodiment, the present disclosure provides a method comprising administering to a patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 µM and about 400 µM. Formulations of dialysis solutions according to the dose ranges claimed in the present disclosure allow therapeutic amounts of pyrophosphate to be delivered to peritoneal dialysis patients.

公开(公告)号：BR112012027092A2

公开(公告)日：2016-07-26

申请号：BR112012027092

申请日：2011-04-22

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： RISER BRUCE L ,  DALTON CHRISTOPHER R ,  WHITE JEFFREY A

IPC: A61K9/08 ,  A61K33/42 ,  A61P9/10

Abstract: métodos e composições para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal. a presente invenção refere-se a métodos e a composições para reduzir, impedir ou reduzir a progressão da calcificação em pacientes de diálise peritoneal. em uma modalidade, a presente invenção apresenta um método que compreende a administração a um paciente, durante a terapia de diálise peritoneal, de uma solução de diálise que compreende uma quantidade terapeuticamente eficaz de pirofosfato que varia entre cerca de 30 m e cerca de 400 m. as formulações de soluções de diálise de acordo com as faixas de dose reivindicadas na presente invenção permitem que quantidades terapêuticas de pirofosfato sejam aplicadas aos pacientes de diálise peritoneal.

公开(公告)号：AU2011242542B2

公开(公告)日：2014-11-27

申请号：AU2011242542

申请日：2011-04-22

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： RISER BRUCE L ,  WHITE JEFFREY A ,  DALTON CHRISTOPHER R

IPC: A61K33/42 ,  A61K9/08 ,  A61P9/10

Abstract: Methods and compositions for reducing, preventing or reducing the progression of calcification in peritoneal dialysis patients are provided. In an embodiment, the present disclosure provides a method comprising administering to a patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 µM and about 400 µM. Formulations of dialysis solutions according to the dose ranges claimed in the present disclosure allow therapeutic amounts of pyrophosphate to be delivered to peritoneal dialysis patients.

公开(公告)号：MX2012012362A

公开(公告)日：2012-11-30

申请号：MX2012012362

申请日：2011-04-22

Applicant: BAXTER INT

Inventor： RISER BRUCE L ,  WHITE JEFFREY A ,  DALTON CHRISTOPHER R

IPC: A61K33/42 ,  A61K9/08 ,  A61P9/10

Abstract: Se proporcionan métodos y composiciones para reducir, evitar o reducir el progreso de la calcificación en pacientes con diálisis peritoneal. En una modalidad, la presente descripción proporciona un método que comprende la administración a un paciente durante la terapia de diálisis peritoneal, una solución que comprende una cantidad terapéuticamente efectiva de pirofosfato que varía entre aproximadamente 30 µM y aproximadamente 400 µM. Las formulaciones de soluciones de diálisis de acuerdo con esos intervalos reclamadas en la presente descripción, permiten que las cantidades terapéuticas de pirofosfato sean administradas a los pacientes con diálisis peritoneal.

公开(公告)号：AU2011242542A1

公开(公告)日：2012-11-08

申请号：AU2011242542

申请日：2011-04-22

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： RISER BRUCE L ,  WHITE JEFFREY A ,  DALTON CHRISTOPHER R

IPC: A61K33/42 ,  A61K9/08 ,  A61P9/10

Abstract: Methods and compositions for reducing, preventing or reducing the progression of calcification in peritoneal dialysis patients are provided. In an embodiment, the present disclosure provides a method comprising administering to a patient during peritoneal dialysis therapy a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 µM and about 400 µM. Formulations of dialysis solutions according to the dose ranges claimed in the present disclosure allow therapeutic amounts of pyrophosphate to be delivered to peritoneal dialysis patients.